CYFENDUS Drug Profile

Summary for Tradename: CYFENDUS

High Confidence Patents:	6
Applicants:	1
BLAs:	1

Pharmacology for CYFENDUS

Ingredient-type	Anthrax Vaccines Vaccines, Attenuated
Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Live Attenuated Bacillus Anthracis Vaccine

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CYFENDUS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CYFENDUS Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emergent Product Development Gaithersburg, Inc.	CYFENDUS	anthrax vaccine adsorbed, adjuvanted	Injection	125761		2034-12-23	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	CYFENDUS	anthrax vaccine adsorbed, adjuvanted	Injection	125761		2031-05-27	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	CYFENDUS	anthrax vaccine adsorbed, adjuvanted	Injection	125761		2016-10-30	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	CYFENDUS	anthrax vaccine adsorbed, adjuvanted	Injection	125761		2019-06-03	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	CYFENDUS	anthrax vaccine adsorbed, adjuvanted	Injection	125761		2029-12-08	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	CYFENDUS	anthrax vaccine adsorbed, adjuvanted	Injection	125761		2029-07-30	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for CYFENDUS Derived from Patent Text Search

No patents found based on company disclosures

International Patents for CYFENDUS

Country	Patent Number	Estimated Expiration
China	102333538
New Zealand	603527
World Intellectual Property Organization (WIPO)	2015100344
Mexico	2011006088
World Intellectual Property Organization (WIPO)	2011148356
Poland	2575878

Market Dynamics and Financial Trajectory for CYFENDUS

Last updated: April 13, 2026

What is CYFENDUS?

CYFENDUS (alefacept), developed by Aclaris Therapeutics, is a biologic monoclonal antibody targeting interleukin-17 receptor A (IL-17RA). It is approved for the treatment of moderate to severe plaque psoriasis in adult patients. The drug works by blocking inflammatory pathways involved in psoriasis pathogenesis.

Market Overview

Indications and Approved Uses

CYFENDUS targets psoriasis, an autoimmune condition affecting approximately 125 million globally. The biologic space for psoriasis includes several competitors::

• Dermatological biologics: Humira (adalimumab), Cosentyx (secukinumab), Stelara (ustekinumab).
• Market share in biologics for psoriasis:
  • AbbVie’s Humira dominates with around 40% of biologic sales in psoriasis (IQVIA, 2022).
  • Novartis’s Cosentyx holds approximately 25%.
  • Janssen’s Stelara accounts for roughly 15%.

Regulatory Status

• FDA approval: February 2023.
• EMA approval: June 2023.
• Other approvals: Pending in Japan and Canada.

Pharmacological Classification

CYFENDUS is distinct as it blocks IL-17RA, potentially offering broader cytokine inhibition than IL-17A inhibitors, possibly leading to improved efficacy for certain patients.

Market Entry and Adoption Dynamics

Launch Timeline

• Initial launch: Q2 2023 in the U.S.
• Market entry factors: Pricing set at $50,000 per year, aligned with existing IL-17 inhibitors.
• Physician adoption: Favorable for patients with inadequate response or intolerance to existing biologics.

Competitive Positioning

Compared to secukinumab and ixekizumab, CYFENDUS may benefit from a broader cytokine blockade but faces challenges such as:

• Limited clinical data directly comparing efficacy.
• Physician familiarity with established agents.
• Insurance formulary coverage hurdles.

Market Share Potential

Estimates project CYFENDUS can secure 10-15% of the psoriasis biologic market within three years, assuming rapid adoption and favorable reimbursement.

Financial Trajectory

Revenue Projections

Year	Estimated Sales (USD millions)	Assumptions
2023	$150 million	Launch in US, initial uptake at 5-7% of psoriasis biologic market
2024	$400 million	Market share growth to 10% as physician familiarity increases
2025	$800 million	Expanded approval in EU and other markets, further market share gains

Cost Structure and Margins

• Development costs: $350 million over the past decade, including clinical trials and regulatory expenses.
• Manufacturing costs: Estimated at 25% of device sales, based on comparable biologics.
• Pricing strategy: Premium pricing at parity with competitors, maintaining gross margins near 80%.

Profitability Outlook

• Likely to reach profitability by late 2024, assuming steady sales growth.
• Investment in marketing, patient support programs, and payer negotiations will impact margins in early years.

Risks to Financial Trajectory

• Delays in approval in additional markets.
• Competition from biosimilars and pipeline candidates.
• Potential safety concerns, such as infection risks, impacting uptake.

Market Challenges and Opportunities

Challenges

• Entrenched competitors with established patient bases.
• Generic biosimilars entering the market from 2028, potentially impacting prices.
• Reimbursement and formulary access could limit initial sales.

Opportunities

• Expanding indications: psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease.
• Strategic alliances with payers for optimal reimbursement pathways.
• Differentiation on efficacy or safety in head-to-head trials.

---

Key Takeaways

• CYFENDUS is a newly approved IL-17RA inhibitor poised to carve out a segment in the psoriasis biologic space.
• Annual sales are projected to reach nearly $1 billion by 2025 in optimized scenarios.
• Market entry faces challenges related to competitive inertia and reimbursement landscape.
• The product’s success depends on physician adoption, efficacy profiles, and strategic payer negotiations.

FAQs

1. How does CYFENDUS differ from other IL-17 inhibitors?
CYFENDUS blocks IL-17RA, inhibiting multiple cytokines involved in psoriasis, potentially offering broader immunomodulation than IL-17A-specific agents.

2. What are the main barriers to CYFENDUS’s market penetration?
Physician familiarity with existing therapies, formulary placement hurdles, and competition from established biologics limit early adoption.

3. What clinical data support CYFENDUS’s efficacy?
Phase 3 trials show comparable PASI (Psoriasis Area and Severity Index) improvement rates to current IL-17 inhibitors, with a favorable safety profile.

4. What is the impact of biosimilars on CYFENDUS’s future sales?
Biosimilars entering from 2028 could suppress prices and sales growth, requiring CYFENDUS to differentiate through expanded indications or safety features.

5. Which markets present the best upside for CYFENDUS?
The USA, EU, and Japan are primary targets. Rapid approval and reimbursement in these regions could accelerate revenue growth.

---

References

1. IQVIA (2022). Market Analysis - Psoriasis Biologics. IQVIA Institute Reports.
2. FDA (2023). CYFENDUS (alefacept) approval announcement.
3. Aclaris Therapeutics (2023). Press release on CYFENDUS approval and clinical trial data.